Movement Disorders

A host of neuropsychiatric disorders are intrinsic to Parkinson disease or occur as a complication of the dopaminergic therapies. Here's what to look for.

Jobs associated with higher economic status appear to be risk factors for these neurologic disorders.

The largest study to date of a potential link between dairy intake and Parkinson disease found that risk varies depending on fat content and total intake. Details here.

Here is evidence that metformin, especially at high doses and for long periods, is associated with increased risk for neurodegenerative diseases and dementia.

New studies shed light on the potential role of monoclonal antibodies in migraine prophylaxis and in Parkinson disease and on a common genetic pathway shared by PD and autoimmune diseases.

These mobile apps provide tools to record medication details and reminders, first aid instructions, step-by-step recovery guides, and other topics of concern for you and your patient.

Researchers tested the accuracy of the Movement Disorder Society’s criteria for diagnosing Parkinson disease.

Studies discussed include neuropsychiatric symptoms leading to mild cognitive impairment and gesture comprehension and language in children with autism.

There is new evidence of a role for viral hepatitis B and C in the development of Parkinson disease.

Researchers studied the complicated relationship between GRIN2A, caffeine consumption, creatine, and progression of Parkinson disease.

From the first hand-held vagus nerve stimulator for episodic cluster headache to a TMS therapy system for depression, we highlight 5 new technologies.

Research at AAN 2017 highlights research of genes that may help predict the likelihood of developing Parkinson disease and progression of the disease.

Patients with Parkinson disease experiencing “off” episodes on levodopa/carbidopa now have another treatment option.

April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.

How frequently are your patients with Parkinson disease reporting pain and is that pain effectively managed?

March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.

Did patients with advanced Parkinson disease switched to extended release carbidopa-levodopa experience clinical benefits?

Studies also include stem cell transplantation for treatment-refractory MS and aspirin use for headache to lessen the need for rescue medication.

Ten general and disease-specific apps for neurologists include assessment scales, anatomical diagrams, and interactive clinical decision support.

Is the parkinsonian phenotype seen in welders related to the exposure of manganese-containing welding fumes?

February news includes stroke risk with Alzheimer disease & migraine, neonatal hemorrhagic stroke, and head trauma in sports.

A phase 3 trial examined the safety and effectiveness of adjunctive opicapone in patients with Parkinson disease treated with levopoda.

Can we see changes in the brain that correspond to cognitive difficulties? Research presented at AAN 2016 offers compelling information.

January news includes the first FDA-approved drug for spinal muscular atrophy, various epilepsy treatments & vitamin D’s impact on Alzheimer & headache.

Orthostatic hypotension’s effect on cognition in Parkinson disease, testing patients with epilepsy who can drive safely, and carotid web are covered.